Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

This is a Quantitative Study study.

Key Points

Paxalisib treatment alters gene expression profiles in tumors, suggesting potential strategies for triple-negative breast cancer.
The analysis identified distinct profiles linked to ezh2 depletion, highlighting the importance of targeted therapies.
Results were derived from NanoString nCounter analysis, emphasizing its role in examining treatment effects.
Findings support ongoing research efforts to improve outcomes in metastatic and immunotherapy-resistant breast cancer.

Analysis reveals gene expression differences in tumors treated with paxalisib, indicating new avenues for overcoming ezh2 and immunotherapy issues.

Supplementary Figure 3. NanoString nCounter analysis highlighting distinct gene expression profiles in Paxalisib-treated tumors.

No takes yet. Share an insight, caveat, or question.

Melino et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share